entertainment -WSS

entertainment

author：explore 2025-10-01 11:01:59 - browse：3711

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

WSS

STAT's guide to the next generation of CAR

Why drug prescriptions should include diagnoses

Ask STAT: What do you want to know about ChatGPT in medicine?

#NeedHerScience: shining a light on gender disparities in medicine

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

knowledge

entertainment

hotspot

Heart attack and stroke risk calculators need revising

Biden administration sends mixed signals on US soldier who crossed into North Korea

Affirmative action in medical school literally saved lives

A Theranos scientist

As demand for Covid shots wanes, Moderna seeks its next success

Twill hunts for pharma partner to market its depression app

Malaria cases in Florida and Texas: Here’s what you need to know

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

How one medical school became remarkably diverse

A look at other Americans who have crossed into North Korea over the years

Wikipedia

Weight bias in eating disorder treatment complicated by new weight loss drugs

Do masks work? RCTs can't tell us

ER docs worry over extreme heat as a 'mass casualty event'

ER docs worry over extreme heat as a 'mass casualty event'

WATCH: Why do fingernails fall off when they're damaged?

Gene therapy has helped boys walk. Can scientists keep it that way?

focus

knowledge

focus

hotspot